Swiss pharmaceutical company Roche said on Saturday its experimental multiple sclerosis drug fenebrutinib met the main goal ...

Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.

Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in ...

For decades, multiple sclerosis (MS) has been defined primarily by its symptoms, rather than its underlying biology. Now, a ...

A new study reveals how Epstein-Barr virus may provoke immune cells to attack the brain, offering fresh hope for treating ...

Could plastic byproducts and forever chemicals found in drinking water cause your body to attack your own nervous system? New ...

Could plastic byproducts and forever chemicals found in drinking water cause your body to attack your own nervous system?

Researchers developed a mouse model of multiple sclerosis that captures the features of progression independent of relapse ...

New research suggests that Epstein-Barr virus may actively provoke the immune system in people with multiple sclerosis. Scientists found large buildups of virus-targeting immune cells in the nervous ...

Researchers at UC San Francisco have uncovered a new clue to how Epstein-Barr virus (EBV) could contribute to multiple ...

Chennai: At 25, Bhanupriya was just another TNPSC aspirant from Madurai, preparing for her exams. One day, she lost partial ...